Equities Analysts Set Expectations for ABOS FY2029 Earnings

On March 28, 2025, analysts from HC Wainwright provided their earnings per share (EPS) estimates for Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS). The analyst, A. Fein, has projected that the company will incur a loss of ($2.03) per share for the fiscal year 2029. They have assigned a "Buy" rating to the stock, alongside a price target of $11.00. This forecast is significant when compared to the current consensus estimate of ($1.56) per share for Acumen's full-year earnings.

Recently, UBS Group revised its target price for Acumen Pharmaceuticals, reducing it from $6.00 to $4.00 while maintaining a "Buy" rating for the stock.

Acumen Pharmaceuticals Trading Performance

As of Monday, shares of NASDAQ:ABOS opened at $1.10, representing a 7.6% decline. The stock has seen a fifty-day simple moving average of $1.37 and a 200-day simple moving average of $1.97. Key financial metrics for Acumen include a quick ratio of 10.43, a current ratio of 10.43, and a debt-to-equity ratio of 0.14. Its market capitalization stands at $66.09 million, with a price-to-earnings ratio of -0.80 and a beta of 0.02. Over the past year, the stock has fluctuated, hitting a low of $1.06 and a high of $4.06.

Acumen Pharmaceuticals recently reported its earnings results on March 27, 2025. The company recorded a loss of ($0.62) per share, which fell short of the analysts' consensus estimate of ($0.47) by a margin of ($0.15).

Hedge Fund Activity

In recent months, institutional investors and hedge funds have altered their positions in Acumen Pharmaceuticals. Geode Capital Management LLC raised its stake by 6.5% in the third quarter, owning 864,528 shares worth approximately $2.14 million after acquiring an additional 52,395 shares. State Street Corp increased its holdings by 18.3%, now possessing 516,406 shares valued at $1.28 million after buying 79,841 shares. SG Americas Securities LLC expanded its investment by 44.2% in the fourth quarter, acquiring 25,631 shares worth $44,000. Barclays PLC boosted its holdings by 189.1%, now holding 61,997 shares worth approximately $154,000. JPMorgan Chase & Co. raised its position by 252.8%, accumulating 63,066 shares valued at $156,000. Notably, 71.01% of the stock is currently held by hedge funds and other institutional investors.

Insider Transactions

Financial activities among insiders have also been noteworthy. CFO Matt Zuga sold 28,902 shares on January 23, 2025, at an average price of $1.72, totaling about $49,711. Following this sale, he retained ownership of 231,744 shares, valued at approximately $398,599.68, a decrease of 11.09% in his holdings. Similarly, CEO Daniel Joseph Oconnell sold 47,778 shares on January 3, 2025, at an average of $1.84, accumulating about $87,911.52. Oconnell now holds 454,707 shares worth around $836,660.88, reflecting a 9.51% drop in his ownership. In the last quarter, insiders sold a total of 131,526 shares, valued at $233,124. Overall, corporate insiders control 7.10% of the company's stock.

Company Overview

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that specializes in developing targeted therapies, particularly for the treatment of Alzheimer’s disease. Its primary focus is on advancing a drug candidate called sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed its Phase I clinical trial to target soluble amyloid-beta oligomers.

Further Insights

• Explore five stocks that outperform Acumen Pharmaceuticals.
• Learn about penny stocks in our comprehensive guide.
• Discover three buyable stocks with strong potential for rebound.
• Stay updated on Congress stock trades.
• Explore Meta’s growing $20 billion AI-Ads venture.
• Understand how to short a stock in five simple steps.
• Get insights into Tesla and Lyft headlines impacting shares.

Stay in the loop about Acumen Pharmaceuticals:

To receive daily updates and news regarding Acumen Pharmaceuticals and related companies, consider subscribing to a free daily email newsletter.

Earnings, Stocks, Acumen